The effects of the multispecies probiotic mixture Ecologic®Barrier on migraine: results of an open-label pilot study
äºBeneficial MicrobesSearch for other papers by N.M. de Roos in
Current site
Google Scholar
Search for other papers by C.G.T. Giezenaar in
Current site
Google Scholar
Search for other papers by J.M.P Rovers in
Current site
Google Scholar
Search for other papers by B.J.M. Witteman in
Current site
Google Scholar
Search for other papers by M.G. Smits in
Current site
Google Scholar
Search for other papers by S. van Hemert in
Current site
Google Scholar
Migraine prevalence is associated with gastrointestinal disorders. Possible underlying mechanisms could be increased gut permeability and inflammation. Probiotics may decrease intestinal permeability as well as inflammation, and therefore may reduce the frequency and/or intensity of migraine attacks. Therefore we assessed feasibility, possible clinical efficacy, and adverse reactions of probiotic treatment in migraine patients. 29 migraine patients took 2 g/d of a probiotic food supplement (Ecologic®Barrier, 2.5Ã109 cfu/g) during 12 weeks. Participants recorded frequency and intensity of migraine in a headache diary and completed the Migraine Disability Assessment Scale (MIDAS) and Henry Ford Hospital Headache Disability Inventory (HDI) at baseline and after 12 weeks of treatment. Compliance was measured every 4 weeks by counting the remaining sachets with probiotics. The study was completed by 27/29 (93%) patients who took 95% of the supplements. Obstipation was reported by 4 patients during the first 2 weeks of treatment only. The mean±standard deviation (SD) number of migraine days/month decreased significantly from 6.7±2.4 at baseline to 5.1±2.2 (P=0.008) in week 5-8 and 5.2±2.4 in week 9-12 (P=0.001). The mean±SD intensity of migraine decreased significantly from 6.3±1.5 at baseline to 5.5±1.9 after treatment (P=0.005). The MIDAS score improved from 24.8±25.5 to 16.6±13.5 (P=0.031). However, the mean HDI did not change significantly. In conclusion, probiotics may decrease migraine supporting a possible role for the intestine in migraine management. Feasibility and lack of adverse reactions justify further placebo-controlled studies.
-
Anderson, R.C., Cookson, A.L., McNabb, W.C., Kelly, W.J. and Roy, N.C., 2010. Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function. FEMS Microbiology Letters 309: 184-192.
'Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function ' () 309 FEMS Microbiology Letters : 184 -192.
-
Bensenor, I.M., Cook, N.R., Lee, I.M., Chown, M.J., Hennekens, C.H. and Buring, J.E., 2001. Low-dose aspirin for migraine prophylaxis in women. Cephalalgia 21: 175-183.
'Low-dose aspirin for migraine prophylaxis in women ' () 21 Cephalalgia : 175 -183.
-
Bussone, G., Diener, H.C., Pfeil, J. and Schwalen, S., 2005. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. International Journal of Clinical Practice 59: 961-968.
'Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials ' () 59 International Journal of Clinical Practice : 961 -968.
-
Covelli, V., Pellegrino, N.M. and Jirillo, E., 2003. A point of view: The need to identify an antigen in psyconeuroimmunological disorders. Current Pharmaceutical Design 9: 1951-1955.
'A point of view: The need to identify an antigen in psyconeuroimmunological disorders ' () 9 Current Pharmaceutical Design : 1951 -1955.
-
DâSouza, A.L., Rajkumar, C., Cooke, J. and Bulpitt, C.J., 2002. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324: 1361.
'Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis ' () 324 BMJ : 1361.
-
De Groot, F.M., Voogt-Bode, A., Passchier, J., Berger, M.Y., Koes, B.W. and Verhagen, A.P., 2011. Headache: the placebo effects in the control groups in randomized clinical trials; an analysis of systematic reviews. Journal of Manipulative and Physiological Therapeutics 34: 297-305.
'Headache: the placebo effects in the control groups in randomized clinical trials; an analysis of systematic reviews ' () 34 Journal of Manipulative and Physiological Therapeutics : 297 -305.
-
Diener, H.C., Tfelt-Hansen, P., Dahlof, C., Lainez, M.J., Sandrini, G., Wang, S.J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D. and Group, M.-S., 2004. Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology 251: 943-950.
'Topiramate in migraine prophylaxis--results from a placebo-controlled trial with propranolol as an active control ' () 251 Journal of Neurology : 943 -950.
-
Duerksen, D.R., Wilhelm-Boyles, C. and Parry, D.M., 2005. Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet. Digestive Diseases and Sciences 50: 785-790.
'Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet ' () 50 Digestive Diseases and Sciences : 785 -790.
-
Elsenbruch, S., Schmid, J., Basler, M., Cesko, E., Schedlowski, M. and Benson, S., 2012. How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women. Neurogastroenterology and Motility 24: 914-e460.
'How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women ' () 24 Neurogastroenterology and Motility : 914 -e460.
-
Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2001. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Available at: http://tinyurl.com/8bccc3r. http://tinyurl.com/8bccc3r
-
Gales, B.J., Bailey, E.K., Reed, A.N. and Gales, M.A., 2010. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Annals of Pharmacotherapy 44: 360-366.
'Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines ' () 44 Annals of Pharmacotherapy : 360 -366.
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514.
'Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic ' () 11 Nature Reviews Gastroenterology and Hepatology : 506 -514.
-
Holroyd, K.A., Penzien, D.B. and Cordingley, G.E., 1991. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31: 333-340.
'Propranolol in the management of recurrent migraine: a meta-analytic review ' () 31 Headache : 333 -340.
-
Hoveyda, N., Heneghan, C., Mahtani, K., Perera, R., Roberts, N. and Glasziou, P., 2009. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology 9: 15.
'A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome ' () 9 BMC Gastroenterology : 15.
-
Hungin, A.P., Mulligan, C., Pot, B., Whorwell, P., Agreus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.M., Rubin, G., Winchester, C. and de Wit, N., 2013. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice â an evidence-based international guide. Alimentary Pharmacology and Therapeutics 38: 864-886.
'Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice â an evidence-based international guide ' () 38 Alimentary Pharmacology and Therapeutics : 864 -886.
-
Jacobson, G.P., Ramadan, N.M., Aggarwal, S.K. and Newman, C.W., 1994. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 44: 837-842.
'The Henry Ford Hospital Headache Disability Inventory (HDI) ' () 44 Neurology : 837 -842.
-
Kerckhoffs, A.P.M., Akkermans, L.M.A., de Smet, M.B.M., Besselink, M.G.H., Hietbrink, F., Bartelink, I.H., Busschers, W.B., Samsom, M. and Renooij, W., 2010. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Digestive Diseases and Sciences 55: 716-723.
'Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs ' () 55 Digestive Diseases and Sciences : 716 -723.
-
Koning, C.J., Jonkers, D.M., Stobberingh, E.E., Mulder, L., Rombouts, F.M. and Stockbrugger, R.W., 2008. The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin. American Journal of Gastroenterology 103: 178-189.
'The effect of a multispecies probiotic on the intestinal microbiota and bowel movements in healthy volunteers taking the antibiotic amoxycillin ' () 103 American Journal of Gastroenterology : 178 -189.
-
Lamprecht, M., Bogner, S., Schippinger, G., Steinbauer, K., Fankhauser, F., Hallstroem, S., Schuetz, B. and Greilberger, J.F., 2012. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial. Journal of the International Society of Sports Nutrition 9: 45.
'Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double-blinded, placebo-controlled trial ' () 9 Journal of the International Society of Sports Nutrition : 45.
-
Launer, L.J., Terwindt, G.M. and Ferrari, M.D., 1999. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 53: 537-542.
'The prevalence and characteristics of migraine in a population-based cohort: the GEM study ' () 53 Neurology : 537 -542.
-
Liévin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D., Neeser, J.-R. and Servin, A.L., 2000. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47: 646-652.
'Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity ' () 47 Gut : 646 -652.
-
Macedo, A., Banos, J.E. and Farre, M., 2008. Placebo response in the prophylaxis of migraine: A meta-analysis. European Journal of Pain 12: 68-75.
'Placebo response in the prophylaxis of migraine: A meta-analysis ' () 12 European Journal of Pain : 68 -75.
-
Mennigen, R. and Bruewer, M., 2009. Effect of probiotics on intestinal barrier function. Annals of the New York Academy of Sciences 1165: 183-189.
'Effect of probiotics on intestinal barrier function ' () 1165 Annals of the New York Academy of Sciences : 183 -189.
-
Miyauchi, E., OâCallaghan, J., Butto, L.F., Hurley, G., Melgar, S., Tanabe, S., Shanahan, F., Nally, K. and OâToole, P.W., 2012. Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain-dependence and attenuation by bacteriocin production. American Journal of Physiology â Gastrointestinal and Liver Physiology 303: G1029-G1041.
'Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain-dependence and attenuation by bacteriocin production ' () 303 American Journal of Physiology â Gastrointestinal and Liver Physiology : G1029 -G1041.
-
Monteith, T. and Goadsby, P., 2011. Acute migraine therapy: new drugs and new approaches. Current Treatment Options in Neurology 13: 1-14.
'Acute migraine therapy: new drugs and new approaches ' () 13 Current Treatment Options in Neurology : 1 -14.
-
Neeser, J.-R., Granato, D., Rouvet, M., Servin, A., Teneberg, S. and Karlsson, K.-A., 2000. Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria. Glycobiology 10: 1193-1199.
'Lactobacillus johnsonii La1 shares carbohydrate-binding specificities with several enteropathogenic bacteria ' () 10 Glycobiology : 1193 -1199.
-
Niers, L., Martin, R., Rijkers, G., Sengers, F., Timmerman, H., van Uden, N., Smidt, H., Kimpen, J. and Hoekstra, M., 2009. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 64: 1349-1358.
'The effects of selected probiotic strains on the development of eczema (the PandA study) ' () 64 Allergy : 1349 -1358.
-
Ohland, C.L. and Macnaughton, W.K., 2010. Probiotic bacteria and intestinal epithelial barrier function. American Journal of Physiology â Gastrointestinal and Liver Physiology 298: G807-819.
'Probiotic bacteria and intestinal epithelial barrier function ' () 298 American Journal of Physiology â Gastrointestinal and Liver Physiology : G807 -819.
-
Parlesak, A., Schafer, C., Schutz, T., Bode, J.C. and Bode, C., 2000. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. Journal of Hepatology 32: 742-747.
'Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease ' () 32 Journal of Hepatology : 742 -747.
-
Persborn, M., Gerritsen, J., Wallon, C., Carlsson, A., Akkermans, L.M. and Soderholm, J.D., 2013. The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 38: 772-783.
'The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis ' () 38 Alimentary Pharmacology and Therapeutics : 772 -783.
-
Pfaffenrath, V., Diener, H.C., Fischer, M., Friede, M., Henneicke-von Zepelin, H.H. and Investigators, 2002. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis â a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 22: 523-532.
'The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis â a double-blind, multicentre, randomized placebo-controlled dose-response study ' () 22 Cephalalgia : 523 -532.
-
Piche, T., Barbara, G., Aubert, P., des Varannes, S.B., Dainese, R., Nano, J.L., Cremon, C., Stanghellini, V., De Giorgio, R., Galmiche, J.P. and Neunlist, M., 2009. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 58: 196-201.
'Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators ' () 58 Gut : 196 -201.
-
Reid, G., Gaudier, E., Guarner, F., Huffnagle, G.B., Macklaim, J.M., Munoz, A.M., Martini, M., Ringel-Kulka, T., Sartor, B., Unal, R., Verbeke, K. and Walter, J., 2010. Responders and non-responders to probiotic interventions: how can we improve the odds? Gut Microbes 1: 200-204.
'Responders and non-responders to probiotic interventions: how can we improve the odds? ' () 1 Gut Microbes : 200 -204.
-
Salim, S.Y. and Soderholm, J.D., 2011. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflammatory Bowel Diseases 17: 362-381.
'Importance of disrupted intestinal barrier in inflammatory bowel diseases ' () 17 Inflammatory Bowel Diseases : 362 -381.
-
Samsam, M., Covenas, R., Ahangari, R. and Yajeya, J., 2010. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry 9: 170-188.
'Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches ' () 9 Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry : 170 -188.
-
Scaldaferri, F., Pizzoferrato, M., Gerardi, V., Lopetuso, L. and Gasbarrini, A., 2012. The gut barrier: new acquisitions and therapeutic approaches. Journal of Clinical Gastroenterology 46 Suppl.: S12-17.
'The gut barrier: new acquisitions and therapeutic approaches ' () 46 Journal of Clinical Gastroenterology : S12 -17.
-
Schellenberg, R., Lichtenthal, A., Wohling, H., Graf, C. and Brixius, K., 2008. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? Headache 48: 118-125.
'Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment? ' () 48 Headache : 118 -125.
-
Sensenig, J., Johnson, M. and Staverosky, T., 2001. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Alternative Medicine Review 6: 488-494.
'Treatment of migraine with targeted nutrition focused on improved assimilation and elimination ' () 6 Alternative Medicine Review : 488 -494.
-
Shuhendler, A.J., Lee, S., Siu, M., Ondovcik, S., Lam, K., Alabdullatif, A., Zhang, X., Machado, M. and Einarson, T.R., 2009. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy 29: 784-791.
'Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials ' () 29 Pharmacotherapy : 784 -791.
-
Stewart, W.F., Lipton, R.B., Whyte, J., Dowson, A., Kolodner, K., Liberman, J.N. and Sawyer, J., 1999. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53: 988-994.
'An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score ' () 53 Neurology : 988 -994.
-
Van Hemert, S., Breedveld, A., Rovers, J., Vermeiden, J., Witteman, B., Smits, M. and de Roos, N., 2014. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Frontiers in Neurology 5: 241.
'Migraine associated with gastrointestinal disorders: review of the literature and clinical implications ' () 5 Frontiers in Neurology : 241.
-
Waeber, C. and Moskowitz, M.A., 2005. Migraine as an inflammatory disorder. Neurology 64: S9-15.
'Migraine as an inflammatory disorder ' () 64 Neurology : S9 -15.
-
Wang, S.J., Chen, P.K. and Fuh, J.L., 2010. Comorbidities of migraine. Frontiers in Neurology 1: 16.
'Comorbidities of migraine ' () 1 Frontiers in Neurology : 16.
-
Wang, X., Shang, D., Ribbing, J., Ren, Y., Deng, C., Zhou, T., Guo, F. and Lu, W., 2012. Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second. European Journal of Clinical Pharmacology 68: 1157-1166.
'Placebo effect model in asthma clinical studies: longitudinal meta-analysis of forced expiratory volume in 1 second ' () 68 European Journal of Clinical Pharmacology : 1157 -1166.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 32 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 920 | 380 | 34 |
| PDFä¸è½½æ¬¡æ° | 859 | 369 | 27 |
The effects of the multispecies probiotic mixture Ecologic®Barrier on migraine: results of an open-label pilot study
äºBeneficial MicrobesSearch for other papers by N.M. de Roos in
Current site
Google Scholar
PubMed
Search for other papers by C.G.T. Giezenaar in
Current site
Google Scholar
PubMed
Search for other papers by J.M.P Rovers in
Current site
Google Scholar
PubMed
Search for other papers by B.J.M. Witteman in
Current site
Google Scholar
PubMed
Search for other papers by M.G. Smits in
Current site
Google Scholar
PubMed
Search for other papers by S. van Hemert in
Current site
Google Scholar
PubMed
Migraine prevalence is associated with gastrointestinal disorders. Possible underlying mechanisms could be increased gut permeability and inflammation. Probiotics may decrease intestinal permeability as well as inflammation, and therefore may reduce the frequency and/or intensity of migraine attacks. Therefore we assessed feasibility, possible clinical efficacy, and adverse reactions of probiotic treatment in migraine patients. 29 migraine patients took 2 g/d of a probiotic food supplement (Ecologic®Barrier, 2.5Ã109 cfu/g) during 12 weeks. Participants recorded frequency and intensity of migraine in a headache diary and completed the Migraine Disability Assessment Scale (MIDAS) and Henry Ford Hospital Headache Disability Inventory (HDI) at baseline and after 12 weeks of treatment. Compliance was measured every 4 weeks by counting the remaining sachets with probiotics. The study was completed by 27/29 (93%) patients who took 95% of the supplements. Obstipation was reported by 4 patients during the first 2 weeks of treatment only. The mean±standard deviation (SD) number of migraine days/month decreased significantly from 6.7±2.4 at baseline to 5.1±2.2 (P=0.008) in week 5-8 and 5.2±2.4 in week 9-12 (P=0.001). The mean±SD intensity of migraine decreased significantly from 6.3±1.5 at baseline to 5.5±1.9 after treatment (P=0.005). The MIDAS score improved from 24.8±25.5 to 16.6±13.5 (P=0.031). However, the mean HDI did not change significantly. In conclusion, probiotics may decrease migraine supporting a possible role for the intestine in migraine management. Feasibility and lack of adverse reactions justify further placebo-controlled studies.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 32 | 0 | 0 |
| å ¨ææµè§æ¬¡æ° | 920 | 380 | 34 |
| PDFä¸è½½æ¬¡æ° | 859 | 369 | 27 |
